The following is a complete listing of all claims in the application, with an indication of the status of each:

Listing of claims:

1. (Currently amended) A method of vaccinating an animal or human in need thereof, comprising the steps of:

providing said animal or human, via mucous membranes of said animal or human, with an antigen; and

providing said animal or human, via mucous membranes of said animal or human, with an adjuvant in the form of ~~The use of~~ a lipopeptide or lipoprotein of the structure (I)



(I)

where

R_1 and R_2, which may be identical or different, are C_{7-25}-alkyl, C_{7-25}-alkenyl or C_{7-25}-alkynyl,

X is S, O or CH_2,

R_3 and R_4 are independently of one another H or methyl and

Y is a physiologically tolerated amino acid sequence which consists of 1 to 25, preferably 12 to 25, amino acid residues and is not immunogenic per se in the species used,

and the asymmetric carbon atom marked with * as the absolute R configuration, according to the Cahn-Inhold-Prelog rule, when X is S (sulfur);

~~as mucosal adjuvant in therapeutic or prophylactic vaccination via the mucous membranes~~.

2. (Currently amended) The method of ~~use as claimed in~~ claim 1, wherein ~~characterized in that~~

the amino acid sequence Y is ~~preferably~~ selected from

a) GQTNT (SEQ ID NO: 1)

b) SKKKK (SEQ ID NO: 2)

c) GNNDESNISFKEK (SEQ ID NO: 3 and

d) GQTDNNSSQSAAPGSGTTNT.(SEQ ID NO: 4).

3. (Currently amended) The method of ~~use as claimed in~~ claim 1, wherein ~~characterized in that~~ the lipoprotein or lipopeptide of structure (I) is an S-[2, 3-bispalmitoyloxy(2R)propyl]cysteinyl-peptide, where the peptide is a physiologically tolerated amino acid sequence which consists of 12 to 25 amino acid residues and is preferably not immunogenic in the species used.

4. (Currently amended) The method of ~~use as claimed in~~ claim 1, wherein ~~characterized in that~~ the ~~mucosal~~ adjuvant is present in a preparation with the antigen ~~actual vaccine component~~, and wherein said providing steps are performed simultaneously by an administration route selected from the group consisting of ~~which is intended for~~ intranasal, intra-NALT, aerosolized oral, intrarectal, conjunctival, intravaginal or intraurethral administration or administration into the milk ducts of the female breast.

5. (Currently amended) The method of ~~use as claimed in~~ claim 1, wherein ~~characterized in that~~ the ~~mucosal~~ adjuvant is present in a kit for coadministration with the antigen, and wherein each of said providing steps are performed by an administration route ~~a vaccine~~ into the milk ducts of the female breast selected from the group consisting of ~~, by the~~ intranasal, intra-NALT, aerosolized oral, intrarectal, conjunctival, intravaginal and ~~or~~ intraurethral ~~route~~.

6. (Currently amended) A method of vaccinating an animal or human in need thereof, comprising the steps of:

providing said animal or human with an antigen component by a non-mucosal route; and

providing said animal or human with an adjuvant in the form of ~~The use of~~ a lipopeptide or lipoprotein of the general structure (I)



(I)

where

R_1 and R_2, which may be identical or different, are C_{7-25}-alkyl, C_{7-25}-alkenyl or C_{7-25}-alkynyl,

X is S, O or CH_2,

R_3 and R_4 are independently of one another H or methyl and

Y is a physiologically tolerated amino acid sequence which consists of 1 to 25, preferably 12 to 25, amino acid residues and is not immunogenic per se in the species used, and the asymmetric carbon atom market with * as the absolute R configuration, according to the Cahn-Ingold-Prelog rule, when X is S (sulfur), excepting an S-(2,3-diacyloxypropyl)cysteinpeptide of the sequence DhcGNNDESNISFKEK (SEQ ID NO: 3), where at least one of the following provisos apply

i) N-terminally the amino ~~acids~~ acid at position ~~positions~~ 2 is absent,

ii) N-terminally the amino acid at position ~~and, where appropriate,~~ 3 ~~are~~ is absent, ~~and/or~~

iii) C-terminally 1 to 2 amino acids are ~~may be~~ deleted~~, as adjuvant in a non-mucosal vaccination~~.

7. (Currently amended) The method of claim 6 wherein said providing an animal or human with an adjuvant step simultaneously provides ~~use as claimed in claim 1, characterized in that the lipopeptide or lipoprotein is present in a preparation with~~ at least one further adjuvant or ~~and/or~~ antigen.

8. (Currently amended) The method of claim 6 wherein ~~use as claimed in claim 1, characterized in that~~ the lipopeptide or lipoprotein is associated or combined with a physical or biological carrier.

9. (Currently amended) The method of claim 6 further comprising the step of providing, together

with ~~use as claimed in claim 1, characterized in that~~ the lipopeptide or lipoprotein, ~~is administered together with~~ one or more anti-inflammatory, antiangiogenic, cytotoxic or immunomodulatory substances, ~~or~~ ligands or ~~with~~ antibodies~~, or is present with these in a preparation~~.

10. (Currently amended) The method of claim 6 further comprising the step of providing the animal or human with ~~use as claimed in claim 1, characterized in that the lipopeptide or lipoprotein is present in a preparation which comprises~~ further additives and excipients~~, in particular preservatives or stabilizers~~.

11. (Currently amended) The method of claim 6 wherein the antigen is present ~~use as claimed in claim 1, characterized in that the vaccine which is accompanied by the adjuvant,~~ in the form of peptides, proteins, DNA, polysaccharides, glycolipids or glycoproteins ~~glucoproteins~~.

12. (New) The method of claim 1 wherein said providing an animal or human with an adjuvant step simultaneously provides at least one further adjuvant or antigen.

13. (New) The method of claim 1 wherein the lipopeptide or lipoprotein is associated or combined with a physical or biological carrier.

14. (New) The method of claim 1 further comprising the step of providing, together with the lipopeptide or lipoprotein, one or more anti-inflammatory, antiangiogenic, cytotoxic or immunomodulatory substances, ligands or antibodies.

15. (New) The method of claim 1 further comprising the step of providing the animal or human with further additives and excipients.

16. (New) The method of claim 1 wherein the antigen is present in the form of peptides, proteins, DNA, polysaccharides, glycolipids or glucoproteins.